Core Insights - BD reported strong financial results for Q3 of fiscal 2025, with revenues of $5.509 billion, reflecting a 10.4% increase compared to the previous year [4][9] - The company raised its full-year adjusted diluted EPS guidance to between $14.30 and $14.45, indicating a growth of 9.4% at the midpoint [9][16] - BD announced a strategic agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation, aiming to enhance its position in the life sciences and diagnostics market [2][10] Financial Performance - Revenues for Q3 2025 were $5.509 billion, up from $4.990 billion in Q3 2024, marking a 10.4% increase [4][9] - Adjusted diluted EPS rose to $3.68, a 5.1% increase from $3.50 in the prior year [4][9] - GAAP diluted EPS increased to $2.00, up 19.0% from $1.68 [4][9] Segment Performance - BD Medical segment revenues reached $2.927 billion, a 14.4% increase from $2.558 billion [8][38] - BD Life Sciences segment revenues were $1.254 billion, slightly down by 0.5% from $1.260 billion [11][38] - BD Interventional segment revenues increased by 7.2% to $1.328 billion from $1.240 billion [11][38] Geographic Performance - U.S. revenues were $3.181 billion, a 10.0% increase from $2.891 billion [6][38] - International revenues grew by 11.0% to $2.328 billion from $2.098 billion [6][38] Strategic Initiatives - The company plans to invest $35 million in a Nebraska facility to enhance production capabilities for its PosiFlush™ Prefilled Flush Syringe [10] - BD Life Sciences submitted an FDA application for the at-home BD Onclarity™ HPV Assay, which includes advanced self-collection technology [10] - The company achieved its Scope 1 and 2 greenhouse gas emissions reduction target for FY 2024, reflecting its commitment to sustainability [10]

Core Insights - BD (Becton, Dickinson and Company) is initiating a patient data registry for the Rotarex™ Atherectomy System to evaluate real-world outcomes for patients with peripheral artery disease (PAD) [1][2]. Group 1: Registry Details - The registry, named "XTRACT," is a prospective, multi-center, single-arm, post-market study aimed at assessing the clinical performance of the Rotarex™ Atherectomy System in treating U.S. patients with PAD lesions [3]. - The XTRACT Registry will enroll up to 600 patients across approximately 100 clinical sites in the United States, with the first patient expected to be enrolled later this year [3]. - Clinical follow-up evaluations will be conducted at 30 days, 6 months, and 12 months post-procedure to assess safety and effectiveness [3]. Group 2: Clinical Significance - The registry aims to provide valuable data to support clinical decision-making and enhance patient outcomes in managing PAD [4]. - The Rotarex™ Atherectomy System is designed to efficiently remove plaque and thrombus in peripheral arteries, serving dual purposes as both an atherectomy and thrombectomy device [4]. - The XTRACT Registry is the first comprehensive registry focused on real-world applications of the Rotarex™ System, highlighting BD's commitment to optimizing treatment strategies in collaboration with leading physicians [5]. Group 3: Industry Context - PAD affects over 21 million Americans and more than 200 million people globally, posing risks of cardiovascular complications and lower limb amputation [5]. - BD's initiative reflects its ongoing commitment to innovative technological development and evidence-based research to support physicians and improve patient outcomes [5].